Operator
Welcome to the Cardiff Oncology Onvansertib Data Update Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to turn the conference over to Candice Masse of Astr Partners. Please go ahead.
Mani Mohindru
Thank you, operator. This is Mani Mohindru from Cardiff. Given the technical difficulties, I’m going to take over. Joining the call today with me from the Cardiff Oncology team will be me, myself, the Interim CEO. In addition, I’m joined with my Chief Medical Officer, Dr. Roger Sidhu; our Chief Scientific Officer, Dr. Tod Smeal; and our newly promoted Chief Accounting Officer, Ms. Brigitte Lindsay, and will also be available during the Q&A session.
During this conference call, we will be making forward-looking statements, including, without limitation, statements related to guidance, results and the timing of data readouts for onvansertib clinical studies. These forward-looking statements are based on the company’s current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of the events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties.
Factors that could cause results to be different from these statements include factors that the
